A correction is reported in comparison with the original version of the paper.

Vitale, A., Emmi, G., Lopalco, G., Fabiani, C., Gentileschi, S., Silvestri, E., Di Scala, G., Iannone, F., Frediani, B., Galeazzi, M., Lapadula, G., Rigante, D., Cantarini, L., Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease (Clinical Rheumatology, (2017), 36, 9, (2063-2069), 10.1007/s10067-017-3627-4), <<CLINICAL RHEUMATOLOGY>>, 2019; 38 (1): 267-267. [doi:10.1007/s10067-018-4302-0] [http://hdl.handle.net/10807/191879]

Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease (Clinical Rheumatology, (2017), 36, 9, (2063-2069), 10.1007/s10067-017-3627-4)

Rigante, Donato;
2019

Abstract

A correction is reported in comparison with the original version of the paper.
2019
Inglese
Vitale, A., Emmi, G., Lopalco, G., Fabiani, C., Gentileschi, S., Silvestri, E., Di Scala, G., Iannone, F., Frediani, B., Galeazzi, M., Lapadula, G., Rigante, D., Cantarini, L., Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease (Clinical Rheumatology, (2017), 36, 9, (2063-2069), 10.1007/s10067-017-3627-4), <<CLINICAL RHEUMATOLOGY>>, 2019; 38 (1): 267-267. [doi:10.1007/s10067-018-4302-0] [http://hdl.handle.net/10807/191879]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/191879
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact